title: Ganciclovir and the treatment of Epstein-Barr virus hepatitis.
abstract: Epstein-Barr virus (EBV) is part of the herpesvirus family that infects up to 90% of the population. Initial infection is often subclincal in children but will generally result in symptomatic infectious mononucleosis in adolescents and adults. Ganciclovir has been utilized in immunocompromised patients with EBV encephalitis and post-liver transplant for EBV fulminant hepatitis. Herein, the successful use of ganciclovir in two immunocompetent patients with severe EBV hepatitis is reported.
authors.affiliation: Department of Gastroenterology and Hepatology, Sir Charles Gardiner Hospital, Nedlands, WA, Australia. leon.adams@uwa.edu.au
authors.forename: Leon A
authors.initials: LA
authors.lastname: Adams
authors.forename: Bastiaan
authors.initials: B
authors.lastname: Deboer
authors.forename: Gary
authors.initials: G
authors.lastname: Jeffrey
authors.forename: Richard
authors.initials: R
authors.lastname: Marley
authors.forename: George
authors.initials: G
authors.lastname: Garas
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir